Brookline, Massachusetts Clinical Trials

A listing of Brookline, Massachusetts clinical trials actively recruiting patient volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 106 clinical trials
TDCS to Improve Motivation and Memory in Elderly (TIME)

Fundamental advancements in understanding successful aging are limited by the lack of causal, rather than just correlational methods to connect age-related changes in memory ability to changes in brain structure and function. In this study, non-invasive electric brain stimulation will be used as a tool to create causal links between …

Northeastern University
 (2.5 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • 1 location
A Study to Evaluate the Safety and Tolerability of Venetoclax Tablets in Combination With Capecitabine Tablets in Adult Participants With Hormone Receptor-Positive HER2-Negative Locally Advanced or Metastatic Breast Cancer Who Had Disease Progression During or After CDK4/6 Inhibitor Therapy

Endocrine therapy is the initial treatment for most hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) breast cancers. This study will evaluate the use of venetoclax in combination with capecitabine in adult participants with HR+, HER2-, metastatic breast cancer (MBC) who had disease progression following treatment …

primary tumor
capecitabine tablets
erbb2
HER2
metastatic breast cancer
Massachusetts General Hospital /ID# 214833
 (4.5 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • +15 other locations
Ibrutinib + Venetoclax in Untreated WM

This study evaluates the safety and efficacy of Ibrutinib combined with Venetoclax (IVEN) in the treatment of adults diagnosed with Waldenstrom's macroglobulinemia (WM) cancer with a specific MYD88 gene mutation. This research study involves an experimental drug combination of targeted therapies. The names of the study drugs involved in this …

growth factor
waldenstrom's macroglobulinemia
ibrutinib
platelet transfusion
absolute neutrophil count
Dana Farber Cancer Institute
 (2.3 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • +1 other locations
MINDFUL-PC for Portuguese Speakers Pilot Study 2020

The study evaluates the effects of the Mindfulness Training for Primary Care (MTPC) Portuguese-adapted version on heart rate variability during a demanding cognitive task. The study also evaluates the effects on mental health, quality of life, self-regulation and behavior outcomes. The study will also complete the MTPC cultural adaptation process …

adjustment disorder
depression
insomnia
stress disorders
anxiety
Cambridge Health Alliance
 (4.2 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • 1 location
CIML NK Cell in Head & Neck Cancer

This research study is evaluating the safety and efficacy of a combination drug and biologic therapy in patients with advanced head and neck cancer. This research study involves the following drugs and biologics: CIML NK donor cells IL-15 superagonist Ipilimumab

prednisone
systemic corticosteroid therapy
biologics
oxygen saturation
immunohistochemistry
Dana Farber Cancer Institute
 (2.5 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • 1 location
Lorlatinib Combinations in Lung Cancer

This research study is evaluating Lorlatinib in combination with Crizotinib or Binimetinib as a possible treatment for either anaplastic lymphoma kinase (ALK)-positive lung cancer or ROS1-positive lung cancer. This research study involves three study drugs. Lorlatinib Binimetinib Crizotinib

metastatic disease
drug test
tyrosine
immunohistochemistry
binimetinib
Beth Israel Deaconess Medical Center
 (2.3 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • +1 other locations
Phase 2 Clinical Trial of Crizotinib for Children and Adults With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas

Subjects with Neurofibromatosis Type 2 (NF2) and progressive vestibular schwannoma (VS) will be treated with crizotinib administered orally. Crizotinib will be taken continuously until disease progression or unacceptable toxicity, in continuous treatment cycles of 28 days each, for a maximum of 12 cycles.

multiple meningiomas
neurofibroma
cataract
glioma
crizotinib
Children's Hospital Boston (Site 725)
 (2.5 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • +16 other locations
Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients

This is a Phase 2 study designed to determine the preliminary anti-tumor activity and confirm the safety of VV1 in combination with cemiplimab. The study will concurrently enroll patients with four distinct advanced malignancies in 5 separate tumor cohorts. The four cancers type are NSCLC and melanoma that are progressing …

antiviral therapy
hepatitis b antigen
endometrial adenocarcinoma
monoclonal antibodies
biomarker analysis
Massachusetts General Hospital Cancer Center
 (4.5 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • +8 other locations
A Study of H3B-6545 in Combination With Palbociclib in Women With Advanced or Metastatic Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer

The primary objective of this study is to evaluate the safety and tolerability of H3B-6545 and palbociclib when administered in combination in order to determine the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of this combination in women with advanced or metastatic estrogen receptor-positive (ER+) HER2- …

growth factor
erbb1
estrogen receptor
breast cancer
cancer
Massachusetts General Hospital
 (4.5 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • +6 other locations
A Study to Evaluate the Safety Pharmacokinetics and Activity of GDC-6036 in Patients With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation

This is a Phase I dose-escalation and dose-expansion study that will evaluate the safety, pharmacokinetics (PK), and preliminary activity of GDC-6036 in patients with advanced or metastatic solid tumors with a KRAS G12C mutation.

kras
solid tumor
kras g12c mutation
ki-ras
metastatic malignant solid tumor
Dana Farber Cancer Institute
 (2.3 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • +7 other locations